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In Parkinson’s disease and dementia with Lewy bodies, a-synuclein aggregates to form oligomers and fibrils; however, the
precise nature of the toxic a-synuclein species remains unclear. A number of synthetic a-synuclein mutations were recently
created (E57K and E35K) that produce species of a-synuclein that preferentially form oligomers and increase a-synuclein-
mediated toxicity. We have shown that acute lentiviral expression of a-synuclein E57K leads to the degeneration of dopamin-
ergic neurons; however, the effects of chronic expression of oligomer-prone a-synuclein in synapses throughout the brain have
not been investigated. Such a study could provide insight into the possible mechanism(s) through which accumulation of
a-synuclein oligomers in the synapse leads to neurodegeneration. For this purpose, we compared the patterns of neurodegen-
eration and synaptic damage between a newly generated mThy-1 a-synuclein E57K transgenic mouse model that is prone to
forming oligomers and the mThy-1 a-synuclein wild-type mouse model (Line 61), which accumulates various forms of a-synu-
clein. Three lines of a-synuclein E57K (Lines 9, 16 and 54) were generated and compared with the wild-type. The a-synuclein
E57K Lines 9 and 16 were higher expressings of a-synuclein, similar to a-synuclein wild-type Line 61, and Line 54 was a low
expressing of a-synuclein compared to Line 61. By immunoblot analysis, the higher-expressing a-synuclein E57K transgenic
mice showed abundant oligomeric, but not fibrillar, a-synuclein whereas lower-expressing mice accumulated monomeric
a-synuclein. Monomers, oligomers, and fibrils were present in a-synuclein wild-type Line 61. Immunohistochemical and ultra-
structural analyses demonstrated that a-synuclein accumulated in the synapses but not in the neuronal cells bodies, which was
different from the a-synuclein wild-type Line 61, which accumulates a-synuclein in the soma. Compared to non-transgenic and
lower-expressing mice, the higher-expressing a-synuclein E57K mice displayed synaptic and dendritic loss, reduced levels of
synapsin 1 and synaptic vesicles, and behavioural deficits. Similar alterations, but to a lesser extent, were seen in the a-synu-
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clein wild-type mice. Moreover, although the oligomer-prone a-synuclein mice displayed neurodegeneration in the frontal cortex
and hippocampus, the a-synuclein wild-type only displayed neuronal loss in the hippocampus. These results support the hy-
pothesis that accumulating oligomeric a-synuclein may mediate early synaptic pathology in Parkinson’s disease and dementia
with Lewy bodies by disrupting synaptic vesicles. This oligomer-prone model might be useful for evaluating therapies directed
at oligomer reduction.
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Abbreviation: SNARE = soluble NSF attachment protein receptor
Introduction
-Synucleinopathies are a heterogeneous group of neurodegen-
erative disorders characterized by widespread neurodegeneration
(Hardy, 2010) and by abnormal accumulation of -synuclein. -
Synuclein is a 14 kDa (Weinreb et al., 1996) synaptic protein (Iwai
et al., 1995) involved in vesicular release (Burre et al., 2010).
Pathological accumulation of -synuclein occurs predominantly in
neuronal cells and synapses, as observed in Parkinson’s disease
and dementia with Lewy bodies (Spillantini et al., 1997; Takeda
et al., 1998), or in glial cells, as observed in multiple system at-
rophy (Papp and Lantos, 1994; Wakabayashi et al., 1998). There
is great interest in what causes -synuclein to undergo conform-
ational changes to form oligomers, protofibrils and fibrils, which
accumulate in cells (Uversky et al., 2001; Tsigelny et al., 2012).
The relative toxic contribution of the different -synuclein arrays,
namely monomers, oligomers and fibrils, has been scrutinized.
Although the precise identification of the toxic -synuclein species
remains unclear, clues to its identity come from familial forms of
-synucleinopathy where mutated forms of -synuclein (A53T,
E46K) (Polymeropoulos et al., 1997) form oligomers faster than
wild-type -synuclein (Conway et al., 1998). Likewise, in sporadic
forms of -synucleinopathies, post-translational modifications
including C-terminus cleavage (Sung et al., 2005), oxidation, ni-
tration (Hodara et al., 2004) and phosphorylation (Fujiwara et al.,
2002) might contribute to oligomerization, polymerization and
toxicity (Paleologou et al., 2010).
In facilitating our ability to study the oligomeric forms of -synu-
clein and to assess its toxic characteristics, we previously generated
variants of -synuclein bearing synthetic mutations (E35K and E57K)
designed to disrupt -synuclein-specific salt bridges and thereby alter
the structure of -synuclein. These mutations resulted in -synuclein
species that specifically formed oligomers but not fibrils (Winner
et al., 2011) and when delivered into the substantia nigra by way
of lentiviral vector injection, led to dopaminergic cell loss. The viral
vector injection system provides information about the acute local
effects of -synuclein oligomers; however, the effects of chronic
and more widespread -synuclein E57K expression in other areas
of the brain associated with dementia with Lewy bodies and the
other -synucleinopathies remain unexamined. A model with these
characteristics could provide insight into the possible mechanism(s)
through which accumulation of -synuclein oligomers in the synapse
leads to neurodegeneration.
In this context, we generated oligomer-prone novel transgenic
mouse lines expressing higher- and lower-levels of human
-synuclein bearing the synthetic -synuclein E57K mutation
under the control of the neuronal mThy-1 promoter, and then
we compared them to -synuclein wild-type mice. -Synuclein
E57K mice displayed synaptic and dendritic loss, reduced levels
of synapsin 1 and synaptic vesicles, and behavioural deficits.
Similar alterations were seen in -synuclein wild-type mice; how-
ever, although oligomer-prone -synuclein mice displayed neuro-
degeneration in the frontal cortex and hippocampus, -synuclein
wild-type mice only displayed neuronal loss in the hippocampus.
These results support the hypothesis that accumulating oligomeric
-synuclein may mediate early neurodegenerative changes by dis-
rupting synaptic vesicles. This oligomer-prone model might be
useful for evaluating therapies directed at oligomer reduction.
Materials and methods
Generation of mThy-1 human
a-synuclein E57K transgenic mice
The University of California at San Diego’s animal subjects committee
approved all experiments. Mice expressing human (h)-synuclein bear-
ing the oligomer-prone E57K mutation under the neuronal mThy-1
promoter cassette (provided by Dr H. van der Putten, Ciba-Geigy,
Basel, Switzerland) were generated. The -synuclein E57K variant
was constructed by site-directed mutagenesis (QuikChange kit;
Stratagene) and confirmed by DNA sequencing (Winner et al.,
2011). The -synuclein E57K complementary DNA fragment was
ligated into pCRII (Invitrogen), sequenced for accuracy, inserted into
the mThy-1 expression cassette between exons 2 and 4, purified, and
microinjected into single-cell embryos (C57BL/6  DBA/2F1)
(Rockenstein et al., 2002). Genomic DNA, extracted from tail biopsies,
was analysed by PCR amplification (Rockenstein et al., 1995; Masliah
et al., 2000). Heterozygous -synuclein E57K mice were crossed with
wild-type (DBA) mice to generate transgenic and non-transgenic lit-
termates. Lines expressing lower (Line 54) and higher (Lines 9 and 16)
levels of -synuclein were selected for analysis compared to our pre-
viously described mThy-1 -synuclein wild-type Line 61 (Rockenstein
et al., 2002), which accumulates various species of -synuclein accom-
panied by axonal pathology, dopaminergic and behaviour deficits
(Games et al., 2013).
Behavioural analysis
Context-dependent learning in an open field data were collected using
a Kinder SmartFrame Cage Rack Station activity monitor system
(Kinder Scientific), in 3D space using a 7  15 beam configuration.
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Data collection began when an animal was placed in the test chamber.
Animals were evaluated for 10 min for three consecutive days, given a
2-day dishabituation period, followed by a fourth trial (Chen et al.,
2012; Sanchez et al., 2012).
Tissue preparation
After behavioural analysis, mice were sacrificed following NIH guide-
lines. The right hemi-brain was post-fixed for 48 h in 4% phosphate-
buffered paraformaldehyde (pH 7.4) at 4C and sagittal sectioned
Vibratome 2000 (40 mm; Leica). The left hemi-brain was snap-frozen
and stored at 70C.
Real-time polymerase chain reaction
RNA was extracted from mice in triplicate using the RNeasy kit
(QIAGEN) (Rockenstein et al., 2002), and quantified by spectropho-
tometer readings. For complementary DNA synthesis, 1 mg total RNA
was reverse transcribed using iScriptTM cDNA Synthesis kit (Bio-Rad).
Real-time PCR experiments were performed using the iQTM5
Detection System (Bio-Rad). Amplification was performed on comple-
mentary DNA equivalent to 25 ng total RNA with 1  iQTM
SYBRGreen Supermix (Bio-Rad). Template PCR reactions were per-
formed in triplicate and run in duplicate using the following PCR
cycling parameters: 50C for 2 min, 95C for 10 min, and 40 cycles
of 94C for 15 s, 60C for 1 min before a dissociation protocol to verify
the presence of a single product for each amplicon. The amount of
complementary DNA was calculated by the comparative threshold
cycle method and expressed using mouse actin as an internal control.
Immunohistochemical analysis
Analysis of -synuclein accumulation was performed using free-float-
ing, blind-coded sections (Ubhi et al., 2010; Masliah et al., 2011).
Sections were incubated overnight at 4C with antibodies against
total -synuclein (1:500, affinity purified rabbit polyclonal, Millipore)
(Masliah et al., 2000), human -synuclein (LB509, mouse monoclo-
nal), and pSer129 -synuclein (mouse monoclonal, Wako laboratories),
followed by biotin-tagged anti-rabbit or anti-mouse IgG1 (1:100,
Vector Laboratories, Inc.) secondary antibodies, Avidin D-HRP
(1:200, ABC Elite, Vector), and visualized with diaminobenzidine.
Sections were scanned with a digital Olympus bright field digital
microscope (BX41).
Neurodegenerative pathology was observed using sections immuno-
labelled overnight with antibodies against the dendritic marker micro-
tubule-associated protein 2 (MAP2; 1:500, Millipore), neuronal marker
NeuN (1:500, Millipore), astroglial marker glial fibrillary acidic protein
(GFAP, 1:1000, Millipore), and synaptic marker synaptophysin (SY38,
1:500, Millipore) (Ubhi et al., 2010; Masliah et al., 2011). Sections
reacted with antibodies against NeuN or GFAP were incubated with
secondary antibodies, Avidin D-HRP, and visualized with diaminoben-
zidine. Sections reacted with antibodies against MAP2 and
synaptophysin were visualized with FITC-tagged secondary antibody
or the Tyramide Signal AmplificationTM Direct (Red) system (1:100,
NEN Life Sciences), respectively, mounted under glass coverslips with
anti-fading media (Vector Laboratories), and imaged with the laser
scanning confocal microscope (MRC1024, Bio-Rad).
The numbers of NeuN-immunoreactive neurons were estimated
using unbiased stereological methods (Overk et al., 2009). Hemi-
sections containing the neocortex, hippocampus and striatum were
outlined using an Olympus BX51 microscope running
StereoInvestigator 8.21.1 software (Micro-BrightField). Grid sizes for
the striatum, frontal cortex, and hippocampal CA3 pyramidal layer
were: 900  900, 800  800, and 300  300mm, respectively, and
the counting frames were 40  40, 30  30, and 50  50 mm, respect-
ively. The average coefficient of error for each region was 0.9.
Sections were analysed using a 100  1.4 PlanApo oil-immersion
objective. A 5-mm high disector, allowed for 2 mm top and bottom
guard-zones.
Double immunolabelling and
fluorescence co-labelling
To determine the co-localization between -synuclein and synaptic
markers, double-labelling experiments were performed (Masliah
et al., 2011). Sections were immunolabelled with antibodies against
human -synuclein (SYN211) and synaptophysin (SY38, Millipore).
To compare the proportion of synapses containing synapsin 1 in
non-transgenic versus -synuclein E57K mice and -synuclein wild-
type mice, double-labelling experiments were performed with antibo-
dies against synapsin 1 and synaptophysin (SY38, Millipore). All
sections were processed simultaneously, and experiments were per-
formed in triplicate. The synaptophysin-immunoreactive terminals
were detected with Tyramide Red (NEN Life Sciences), whereas
SYN211 and synapsin 1 were detected with FITC-tagged antibodies
(1:75, Vector). Sections were imaged with a Zeiss  63 1.4 objective
on an Axiovert 35 microscope (Zeiss) with an attached MRC1024 laser
scanning confocal microscope system (Bio-Rad) (Masliah et al., 2011).
Paired optical sections were analysed with ImageJ co-localization
colour map software to determine the per cent of synaptophysin-
positive terminals containing -synuclein- or synapsin -1-immunoreac-
tivity. For each mouse, 20 digital images, each containing 700
synapses on average, were analysed. Per cent neuropil was calculated
based on area of intensity above threshold divided by the geometric
area.
Tissue fractionation, immunoblot
analysis and size exclusion
chromatography
Conventional immunoblot
The distribution and levels of -synuclein in mouse brains were ana-
lysed using lysate that were extracted and fractioned into soluble and
insoluble fractions by ultracentrifugation (Masliah et al., 2011). Protein
(20 mg/lane) was loaded onto 4–12% SDS/PAGE gels and blotted onto
polyvinylidene difluoride membranes, incubated with rabbit polyclonal
anti--synuclein (1:1000; Millipore) or mouse monoclonal -synuclein
antibody (1:1000; BD), followed by HRP-tagged secondary antibodies
(1:5000; Santa Cruz Biotechnology). Bands were visualized by
enhanced chemiluminescence (PerkinElmer) and analysed with a quan-
titative Versadoc XL imaging apparatus (Bio-Rad). b-Actin (1:3000)
was the loading control.
Sequential extraction
Oligomers were evaluated using additional immunoblot analysis of
protein following three sequential extractions to generate Tris-buffered
saline (TBS)-, TBST-, and urea-soluble fractions (Tofaris et al., 2006).
Protein extracts were run on 4–12% Bis-Tris gels (Invitrogen) and
electroblotted onto nitrocellulose membranes (Millipore). Membranes
were fixed in 0.4% paraformaldehyde for 30 min (Lee and Kamitani,
2011), washed in PBS, and blocked for 30 min in PBS Tween (PBS with
0.2% Tween-20, and 5% bovine serum albumin), followed by
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incubation with either SYN211 (1:600; Sigma) or human- and
rodent-specific antibody SYN1 (1:1000; BD Bioscience in PBS Tween
containing 5% bovine serum albumin) overnight. After washing with
PBS Tween, membranes were probed with anti-mouse secondary anti-
bodies (1:5000, American Qualex), normalized as above and
quantified (Nuber et al., 2008).
Native gel electrophoresis was conducted on 12% Tris-glycine gels
with native (SDS-free) running and sample loading buffer (Invitrogen)
(Fauvet et al., 2012).
Sequential homogenates were further fractionated by size exclusion
chromatography using a S200 10/300 GL column (GE Healthcare),
previously equilibrated in TBS + buffer with 0.05% (w/v) sodium
azide. Elution was performed at 0.5 ml/min monitoring UV signals at
280 nm and 260 nm. Fractions of 0.5 ml were collected during elution,
starting at 6 ml (just before the void volume) and ending at 22 ml
(close to the end of the column). Aliquots of the eluted fractions
were then used for SDS-PAGE and western blot analyses. LB509
from Abcam was used as primary antibody.
Cases with dementia with Lewy bodies
For comparison with the sequential immunoblot assay in the
-synuclein mice, frozen samples from the right hemisphere from six
dementia with Lewy bodies cases were obtained from patients evalu-
ated neurologically and psychometrically at the Alzheimer Disease
Research Centre, University of California, San Diego (Hansen, 1997).
Control cases were obtained from the German Brain Bank. The diag-
nosis was based on the clinical presentation of dementia and the
pathological findings of Lewy bodies were detected with antibodies
against -synuclein, as recommended (McKeith et al., 1996). Tissue
was sequentially extracted and 25mg of TBS and urea extracts used for
immunoblot studies, as described above (Nuber et al., 2013).
Fibril assembly
For generation of a dot blot standard, fibrils were prepared using
1 mg/ml -synuclein monomer in assembly buffer (50 mM Tris,
100 mM NaCl, pH 7.0) and agitated (37C; 1000 rpm). Reaction was
stopped after 3 days, diluted with PBS (10mM final concentration) and
stored at 20C. A short sonication with a tip sonicator (Fisher
Scientific) increased the dissociation of small oligomers to generate
‘seeds’.
Dot blot analysis
Formation of -synuclein oligomers was determined using dot blot
measurements with the A11 antibody (1:4000; BioSource) (Kayed
et al., 2003). Duplicate cytosolic or hippocampal TritonTM X-100
membrane fractions (8 mg) were spotted on a polyvinylidene difluoride
membrane, blocked for 30 min with 5% bovine serum albumin in PBS
Tween, incubated with A11 for 1.5 h at room temperature, and trea-
ted with HRP-conjugated anti-rabbit IgG for 45 min. Bands were visua-
lized with enhanced chemiluminescence, and analysed using Image
Quant Software (Amersham Bioscience).
Electron microscopy and immunogold
analysis
Vibratome sections from the non-transgenic and -synuclein E57K
mice (Line 16) were post-fixed in 1% glutaraldehyde, treated with
osmium tetroxide, embedded in Epon araldite and sectioned with
the ultramicrotome (Leica) (Masliah et al., 2011). Grids were analysed
with a Zeiss OM10 electron microscope (Rockenstein et al., 2001).
These same serial sections were used for analysis of synaptic vesicle
counts (Applegate and Landfield, 1988). Approximately 100 terminals
and 2500 vesicles were analysed per animal. Immunogold-labelled sec-
tions were mounted on nickel grids, etched and incubated with the
LB509 antibody (1:50) and labelled with 10 nm Aurion ImmunoGold
particles (1:50, Electron Microscopy Sciences) with silver enhancement.
Electron micrographs (25 000 magnification) were obtained.
Statistical analysis
All analyses used GraphPad Prism (version 5.0). Differences among
means were assessed by one-way ANOVA with Dunnett’s post hoc
test when compared to non-transgenic and by Tukey-Kramer when
comparing transgenic groups. Two-way ANOVA with repeated meas-
ures followed by a Bonferroni multiple comparisons post hoc test was
used for analysing the interactions between groups and time. The null
hypothesis was rejected at the 0.05 level.
Results
Characterization and comparison of
messenger RNA and protein expression
in transgenic mouse lines expressing
the a-synuclein E57K mutation versus
wild-type a-synuclein
To investigate the effects of chronic widespread expression of oligo-
mer-prone -synuclein, we generated novel transgenic mouse lines
(Lines 9, 16 and 54) expressing the -synuclein E57K mutation under
the control of the neuronal mThy-1 promoter (Fig. 1A), and analysed
them with mThy-1 -synuclein wild-type Line 61 for expression of -
synuclein at the messenger RNA (Fig. 1B) and protein levels (Fig. 1C).
Quantitative PCR analysis of messenger RNA isolated from brain
tissue demonstrated that -synuclein E57K Lines 9 and 16 were
higher-expressing lines, similar to -synuclein wild-type Line 61
(Fig. 1B) (Rockenstein et al., 2002), whereas -synuclein E57K Line
54 was a low-expressing line producing a fifth of the Line 61 expres-
sion (Fig. 1B). Consistent with the quantitative PCR results, immuno-
blot analysis demonstrated that -synuclein E57K Lines 9 and 16 and
-synuclein wild-type Line 61 expressed significantly higher levels
of -synuclein compared to non-transgenic mice (Fig. 1C–F).
-Synuclein was primarily found in the cytosolic fraction, and the
most abundant band was detected at 14 kDa, corresponding to
monomeric -synuclein (Fig. 1C and D). Other bands between 28
and 62 kDa were found in the Lines 9 and 16 and, to a lesser extent,
in Line 61. In the membrane fraction, the 14 kDa band was detected
to a significantly greater extent in -synuclein E57K Lines 9 and 16
and -synuclein wild-type Line 61, but not in Line 54 (Fig. 1E and F).
Compared to the -synuclein E57K lines, the -synuclein wild-type
mice displayed a prominent band at 28 kDa in the membrane fraction
(Fig. 1E). Levels of -synuclein protein in -synuclein E57K Lines 9
and 16 were comparable to those observed in -synuclein wild-type
mice (Line 61; Fig. 1E and F).
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Characterization of a-synuclein
aggregates in the a-synuclein E57K
transgenic mouse lines
To investigate the formation of -synuclein aggregates in the
-synuclein E57K mice, we performed sequential extraction
procedures with detergent-containing buffers yielding three main
extracts. The first extract was enriched in TBS-soluble cytosolic
proteins, the second extract contained TritonTM X-100-soluble
membrane and organelle proteins, and the third extract contained
SDS/urea-soluble proteins, including integral membrane proteins
and cytoskeletal filaments (Schindler et al., 2006). In urea-treated
extracts, complex -synuclein aggregates typically solubilize as a
high-molecular weight band and its monomer (Culvenor et al.,
1999; Campbell et al., 2001; Kahle et al., 2001; Liu et al.,
2005; Tong et al., 2010) (Fig. 2A). Western blot analyses of the
TBS-soluble extracts of hippocampi showed a similar band at
14 kDa in Lines 9, 16 and 61 (Fig. 2A). Incubation with the
human-specific anti--synuclein with the urea-soluble fraction
showed a specific band running at 70 kDa molecular weight
Figure 1 Generation of transgenic mice expressing the synthetic -synuclein mutation E57K under the mThy-1 promoter. (A) Diagram of
the mThy-1 construct. (B) Levels of -synuclein messenger RNA expressed as a ratio to the housekeeping gene Gadph in non-transgenic
and -synuclein E57K Lines 9, 16, and 54, showing that Line 54 had 0.2 of the expression compared to -synuclein E57K Line 9 and 16
and -synuclein wild-type Line 61 transgenic mice. (C) Representative western blot (SDS) and (D) analysis of the levels of -synuclein in
the cytosolic fractions showing that Lines 9 and 16 were higher expressers of -synuclein monomers and dimers, which was to a similar
extent as Line 61. (E) Representative western blot (SDS) and (F) analysis of levels of monomer, dimer, and oligomer -synuclein
immunoreactivity in the membrane-bound fractions. Across all lines monomeric -synuclein (14 kDa) was present to a greater extent in the
cytosolic fraction compared to the membrane fraction. For analysis, six non-transgenic and six mThy-1 -synuclein E57K transgenic mice
(3–4 months old) from each line were used. *P50.05 when compared to non-transgenic control using one way ANOVA with Dunnet’s
post hoc test. Tg = transgenic; wt = wild-type.
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marker in -synuclein E57K Lines 9 and 16 mice, consistent with
pentamer -synuclein conformer (Fig. 2B), which was also present
in cases with dementia with Lewy bodies (Fig. 2C). Although urea-
soluble fraction from -synuclein wild-type Line 61 mice had a
strong band at 14 kDa (Fig. 2B), it was faint in the -synuclein
E57K, non-transgenic lines, and dementia with Lewy body cases
(Fig. 2C). Immunoblot analysis of -synuclein in native gels was
consistent with previous studies (Fauvet et al., 2012), which
showed a faint band at 55 kDa for Lines 9, 16 and 54, and a
dense smear was most prominent in Lines 9 and 16 between 70–
200 kDa. In the -synuclein wild-type transgenic line, there was a
prominent band at 55 kDa, but a less prominent smearing
between 70–200 kDa (Fig. 2D). In agreement with the immuno-
blot analysis, dot blot analysis with the antibody against oligomers
(A11) showed the presence of abundant immunoreactive material
in the TBS-soluble fraction in Lines 9, 16, 54 and 61 transgenic
mice, but not in the non-transgenic controls (Fig. 2E and F).
Although Line 61 had significantly less oligomeric protein com-
pared with Line 16 (Fig. 2E and F), analysis for the presence of
fibrils (FILA-1) indicated that only Line 61 had a significant level
compared to non-transgenic background (Fig. 2E and G). Size
exclusion chromatography using homogenates that were biochem-
ically fractionated into soluble (Fig. 3A and B) and urea (Fig. 3C
and D) fractions further confirmed that -synuclein E57K mice
were more prone to form oligomeric -synuclein compared to
the -synuclein wild-type line.
Patterns of a-synuclein immunoreactiv-
ity and distribution in a-synuclein E57K
transgenic compared with a-synuclein
wild-type transgenic mice
To analyse the anatomical distribution of -synuclein in the -
synuclein E57K mice, sections were immunolabelled with antibo-
dies against total -synuclein. As expected, in the non-transgenic
mice the antibody against total -synuclein reacted mildly with
fine granular structures in the neuropil throughout the CNS,
Figure 2 Immunoblot analysis of -synuclein oligomers in the -synuclein E57K and -synuclein wild-type transgenic mice. (A) Western
blot evaluation indicated that all transgenic lines were positive for human -synuclein, which was absent in the non-transgenic mice;
whereas all mouse lines were positive for total -synuclein. (B) After urea extraction, -synuclein E57K Lines 9 and 16 had bands 70 kDa
(pentamers), which were not present in the lower-expressing -synuclein E57K Line 54, -synuclein wild-type or non-transgenic mice, but
which were present (C) in frontal cortex from controls and cases with dementia with Lewy bodies. (D) Analysis of -synuclein in native gel
reveals a faint band at 55 kDa for Lines 9, 16, and 54; a dense smear between 70 and 200 kDa was most prominent in Lines 9 and 16.
In the -synuclein wild-type animal line, there was a prominent band at 55 kDa and less smearing between 70 and 200 kDa.
(E) Representative image of the dot blot analysis with the A11 and FILA-1 antibodies using TritonTM X-100 membrane-extracted fraction
indicated that -synuclein oligomers (F) were present in all -synuclein E57K transgenic lines, and Line 61, albeit to a lesser extent than in
Line 16. (G) Only Line 61 had significant levels of fibrils above non-transgenic background. Seeded and fibrillized dose responses of
recombinant -synuclein protein were generated for qualitative concentration analysis. For analysis, four non-transgenic and six transgenic
mice (3–4 months old) from each line were used. Tg = transgenic; wt = wild-type * = p-value 50.05 compared to non-tg; # = p-value
5 0.05 compared to Line 61.
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Figure 3 Separation of oligomeric and monomeric species in extracts of wild-type and E57K transgenic mice using size exclusion
chromatography-profiles (top) before western blot (bottom). (A) -Synuclein extracted from -synuclein wild-type mice with TBS + buffer
was found as monomers and small oligomers (lanes 4 and 5). (B) -Synuclein E57K-transgenic mice brain extracts contained monomeric
-synuclein (lane 5 bottom) and oligomers with a molecular weight 4200 kDa, which elute near the void volume and are retained in the
stacking gel of standard SDS-PAGE (lanes 1–2). (C) Eluted fractions from urea-soluble extracts of -synuclein wild-type transgenic mice
reveal a monomeric -synuclein band (lane 4) in addition to an intense absorbance peak near the void volume. (D) Eluted fractions from
urea-soluble extracts of -synuclein E57K transgenic mice also had an intense absorbance peak near the void volume although the
oligomeric species were bigger in size than those extracted from wild-type transgenic mice (compare lanes 1–2 of C with lanes 1–4 of D).
There was no evidence of a band corresponding to monomeric -synuclein in the -synuclein E57K transgenic urea-soluble homogenates.
EV = elution volume; HMW = high molecular weight; tg = transgenic; WB = western blot; wt = wild-type.
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consistent with the distribution of the endogenous murine
-synuclein (Fig. 4A–D). Transgenic -synuclein E57K mice from
Lines 9 and 16 displayed intense immunoreactivity within the
neuropil in the neocortex (Fig. 4A and B), limbic system (Fig. 4A
and C), basal ganglia (Fig. 4A and C), thalamus and substantia
nigra pars compacta (Fig. 4A and D), whereas -synuclein was not
observed in most neuronal cells bodies in any of the -synuclein
E57K lines (Fig. 4B and C), although occasionally there were -
synuclein-positive neuronal cell bodies in the substantia nigra (Fig.
4C). Consistent with the immunoblot analysis, mice from Line 54
showed a similar distribution of -synuclein, but to a lesser extent
than Lines 9 and 16 (Fig. 4). In contrast, tissue from Line 61 over-
expressing -synuclein wild-type mice (Rockenstein et al., 2002)
showed intense immunoreactivity that was detected in the neuro-
pil and in neuronal cell bodies, in some instances mimicking intra-
cellular inclusions (Fig. 4B–D arrows).
To further investigate the presence and distribution of
-synuclein aggregates in the brains of the -synuclein E57K
mice, immunocytochemical analysis was performed in sections
pretreated with proteinase K. Previous studies have shown that
-synuclein aggregates are proteinase K resistant (Takeda et al.,
1998; Kahle et al., 2001). As expected, in untreated (proteinase
K ) sections from the -synuclein E57K mice, most -synuclein
immunoreactivity was present in the presynaptic terminals
(Fig. 5A), whereas in the -synuclein wild-type mice, -synuclein
was detected in the neuropil and neuronal cell bodies (Fig. 5A).
After treatment (proteinase K + ), -synuclein immunoreactivity in
the synapses of the non-transgenic and -synuclein mice was
considerably reduced; however, in the higher-expressing (Lines 9
and 16) -synuclein E57K mice we noticed the appearance of
abundant, enlarged and tortuous neurites, but not in the low
expressing line (Line 54; Fig 5A). Similarly, in the -synuclein
Figure 4 Comparison of the patterns of -synuclein distribution in the brains of the -synuclein E57K and -synuclein wild-type trans-
genic mice. Vibratome sections were immunostained with the rabbit polyclonal antibody (Millipore) against full-length total -synuclein.
(A) Low-magnification photomicrographs of regions of interest, including the neocortex (1), hippocampus (2), striatum (3) and (4)
thalamus in the non-transgenic -synuclein E57K and -synuclein wild-type transgenic mice. (B) Staining against -synuclein was present
in the neuropil of the neocortex in Lines 9 and 16, and to a lesser extent in Line 54, whereas in the -synuclein wild-type transgenic Line 61
mouse model, -synuclein immunoreactivity was present in the neuropil and neuronal cell bodies (arrow). The inset box illustrates a
detailed area at higher magnification. (C) Immunoreactive -synuclein punctae were also present in the neuropil of the hippocampus and
striatum in Lines 9 and 16, and to a lesser extent in Line 54, whereas in the -synuclein wild-type transgenic Line 61 mice, -synuclein
immunostaining was also present in neuronal cell bodies (N) and dystrophic neurites (arrows). (D) -Synuclein was present in the neuropil
of the thalamus in Lines 9 and 16, and to a lesser extent in Line 54, and occasionally in the cell bodies in the substantia nigra pars compacta
(insets) whereas in the -synuclein wild-type transgenic Line 61 tissue, -synuclein immunostaining was present in the neuropil and
dystrophic neurites. In the substantia nigra pars compacta, -synuclein accumulated in the neuronal cell bodies (arrows). For analysis, six
non-transgenic, n = 6 -synuclein E57K transgenic mice from each line and six -synuclein wild-type transgenic Line 61 mice (8–10
months old) were used. Scale bars: A = 150 mm; B = 25 mm; C = 50; D = 25 mm.
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wild-type mice, proteinase K pretreatment resulted in the appear-
ance of -synuclein-positive granular structures in the neuropil,
whereas the neuronal and synaptic -synuclein labelling was
reduced (Fig. 5A). The proteinase K-resistant -synuclein neurites
were most abundant in the neocortex (Fig. 5A), in the hippocam-
pal molecular layer and lacunosum, and in the basal ganglia and
substantia nigra (not shown). In agreement with these findings,
analysis with the LB509 antibody, which could detect pathological
as well as other types of human -synuclein (Jakes et al., 1999),
showed the presence of abundant immunoreactive granular struc-
tures in the neuropil of the -synuclein E57K mice (Fig. 5B). In the
-synuclein wild-type mice, LB509 reacted with the neurites in the
neuropil, as well as with the neuronal cell bodies (Fig. 5B).
Similarly, immunostaining with an antibody against phosphory-
lated -synuclein (Ser129) showed the presence of abnormal
immunoreactive neurites in the higher-expressing -synuclein
Figure 5 Accumulation of proteinase K-resistant -synuclein in the -synuclein E57K transgenic mice. (A) Representative photomicro-
graphs (frontal cortex) of brain sections from non-transgenic and -synuclein transgenic mice immunostained with the -synuclein
polyclonal antibody (Millipore) without proteinase K (PK , top) and with proteinase K (PK + , bottom) treatment. In the proteinase
K-treated tissue from non-transgenic and -synuclein transgenic mice, the antibody stained the neuropil as well as the neurons (n) in the
Line 61 mice. The proteinase K + treatment eliminated most of the neuropil immunostaining in the non-transgenic mice, while at the same
time revealing -synuclein in axons (arrowheads), as well as in dystrophic neurites in the neuropil of the -synuclein E57K transgenic Lines
9 and 16 and the -synuclein wild-type transgenic Line 61 mice. (B) Patterns of LB509 (pathological -synuclein, top) immunostaining in
the neocortex of the non-transgenic and -synuclein transgenic mice. The non-transgenic mice did not immunoreact with the LB509
antibody, whereas in the -synuclein E57K transgenic mice, -synuclein immunostaining was present in the neuropil. The -synuclein
wild-type transgenic Line 61 mice displayed -synuclein accumulation in the neuron cell body (n) and neuropil. Patterns of p129S
-synuclein immunostaining in the neocortex of the non-transgenic and -synuclein transgenic (bottom) indicated that the non-transgenic
mice showed no labelling with the pSer129 antibody whereas the -synuclein E57K transgenic mice showed -synuclein immunostaining
in the neuropil (arrowheads). The -synuclein wild-type transgenic Line 61 mice presented -synuclein accumulation in the neuron cell
body (n) and neuropil. Scale bar = 10 mm. Four non-transgenic and four -synuclein E57K transgenic mice (8–10 months old) from each
line were used. Tg = transgenic; wt = wild-type.
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E57K mice (Fig. 5B). In the -synuclein wild-type mice, the
pSer129 antibody reacted with the neurites as well as with the
neuronal cell bodies (Fig. 5B).
To analyse the distribution of the transgenic human -syn, im-
munofluorescent and confocal analysis was performed with the
SYN211 antibody. Using confocal microscopy we found close
co-localization between human -synuclein (SYN211) and synap-
tophysin in the neocortex (Fig. 6A), hippocampus (Fig. 6B) and
other brain regions (not shown) in all three lines of -synuclein
E57K mice, as well as in the -synuclein wild-type expressing Line
61, indicating the accumulation of -synuclein in the synapse.
However in the latter mouse line, -synuclein also accumulated
in the neuronal cell bodies (Fig. 6).
Accumulation of oligomer-prone
a-synuclein results in synaptic
pathology and reduced vesicles
To determine if the accumulation of oligomerization prone -synu-
clein E57K in the synapses led to neurodegenerative pathology,
immunohistochemical analysis was performed (Fig. 7). As we were
interested in the chronic effects of a more global accumulation of
-synuclein accumulation in brain regions relevant to dementia
with Lewy bodies and Parkinson’s disease with dementia, analyses
hereafter were performed in the frontal cortex and hippocampus.
Confocal analysis of synaptic terminals with an antibody against
synaptophysin showed a significant 20–40% loss in the frontal
cortex in the higher-expressing Lines 9 and 16, as well as Line
61, but not in Line 54 (Fig. 7A and C). In the hippocampus there
was a similar loss in Lines 16 and 61, but not Lines 9 or 54
(Fig. 7C). Likewise, analysis of dendrites with an antibody against
MAP2 displayed a significant 20–40% loss in the frontal cortex of
the higher-expressing Lines 9 and 16, as well as Line 61, but not
in Line 54 (Fig. 7C). In the CA1-CA3 regions of the hippocampus,
there was a significant reduction across all lines (Fig. 7B and C).
As the higher-expressing -synuclein E57K mice displayed synaptic
accumulation of -synuclein accompanied by decreased synaptophy-
sin and MAP2 immunoreactivity, and as we have previously shown
that accumulation of -synuclein oligomers impairs the transport of
synaptic proteins (Scott et al., 2010), immunoblot analysis was per-
formed using fronto-temporal cortex. Levels of synaptophysin showed
a trend toward a reduction in Line 9 as well as Line 61 and were
significantly reduced by 20% in Line 16 (Fig. 8A and B). In Lines 9
and 16, as well as Line 61, levels of synapsin 1 were significantly
Figure 6 Immunocytochemical analysis of the synaptic co-localization between synaptophysin and -synuclein in the -synuclein E57K
and -synuclein wild-type transgenic mice. Sections were double-labelled with antibodies against synaptophysin (SY38, red channel) and
human -synuclein (SY211, green channel) and imaged with the laser scanning confocal microscope. (A) Comparison of the patterns of
co-localization between synaptophysin and -synuclein in layer II of the neocortex across all transgenic mouse lines. The transgenic lines
displayed extensive co-localization between the two synaptic markers. The split image in the column to the left (red) is synaptophysin, in
the centre is human -synuclein and to the right is the two channels merged. The box represents the magnified merged image. (B)
Comparison of the patterns of co-localization in the CA1 region of the hippocampus across the -synuclein E57K and -synuclein wild-
type transgenic mouse lines. All transgenic lines displayed extensive co-localization between the two synaptic markers. Six non-transgenic
-synuclein E57K transgenic mice from each line and six -synuclein wild-type transgenic Line 61 mice (8–10 months old) were used for
analysis. Scale bars in the single channel images = 25mm; 5mm in the enlarged merged images. Tg = transgenic; wt = wild-type.
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reduced by 30–50%, and levels of RIMS3 were significantly reduced
by 55% in Line 16 (Fig. 8A and B). In contrast, levels of SNAP25 were
not altered when compared to non-transgenic controls (Fig. 8A and B).
Further analysis of the frontal cortex using double-labelling and con-
focal microscopy confirmed that the proportion of synaptophysin
(SY38) immunoreactive terminals containing synapsin 1 was signifi-
cantly decreased by 50–60% in the higher-expressing Lines 9 and 16,
as well as the -synuclein wild-type Line 61 (Fig. 8C and D), compared
with non-transgenic controls and the lower-expressing Line 54.
To further investigate alterations in the synaptic terminals of the
-synuclein E57K mice, ultrastructural analysis was performed
using transmission electron microscopy (TEM) and immunogold.
Compared to non-transgenic controls (Fig. 9A), mice from
higher-expressing -synuclein E57K Lines 9 and 16, as well as -
synuclein wild-type Line 61, showed synaptic accumulation of
electro-dense bodies. In addition, Lines 9, 16 and 61 showed a
significant reduction in the numbers of synaptic vesicles in the
nerve terminals (Fig. 9A). To ascertain if these ultrastructural
alterations in the presynaptic terminals were associated with the
accumulation of -synuclein, immunogold analysis was performed
using an antibody against pathological -synuclein (LB509)
(Fig. 9C and D). In the higher-expressing -synuclein E57K and
-synuclein wild-type Line 61 mice, abundant gold particles were
detected in the enlarged nerve terminals that displayed distended
vesicles (Fig. 9C and D), compared with the non-transgenic con-
trols (Fig. 9C). Taken together these results are consistent with the
double-labelling and confocal studies, indicating that accumulation
of oligomer-prone -synuclein E57K disturbs synaptic vesicles.
Similar effects were observed in -synuclein wild-type Line 61
Neuronal loss pathology in a-synuclein
E57K mice
To determine if the alternations in the synapses (Figs 7–9) had an
effect on neuron cell bodies, stereological assessment of NeuN-
Figure 7 Analysis of synapto-dendritic loss in the frontal cortex and hippocampus from -synuclein E57K and -synuclein wild-type
transgenic mice. Sections were immunolabelled with antibodies against synaptophysin (SY38) and MAP2, and imaged with a laser
scanning confocal microscope. (A) Representative photomicrographs of the presynaptic terminals (SY38) and (B) dendrites (MAP2) in the
hippocampus. Arrows indicate areas of dendritic loss in Line 16 in the CA2-3 region. Analysis was expressed as per cent area of the
neuropil. (C) Compared with non-transgenic controls, -synuclein E57K transgenic mice from Lines 9 and 16, as well as -synuclein wild-
type Line 61, displayed a significant reduction in synapotophysin in the frontal cortex, whereas line 54 (lower-expressing) was comparable
non-transgenic littermates. In the hippocampus (hippo), synaptophysin was reduced in -synuclein E57K Line 16 and the -synuclein wild-
type Line 61. (D) MAP2 was reduced in the frontal cortex in -synuclein E57K Lines 9 and 16, as well as -synuclein wild-type Line 61, but
not in -synuclein E57K Line 54. In the hippocampus, MAP2 was reduced across all transgenic lines. n = 8 mice per group, age 8–10
months. *P5 0.05 when compared with non-transgenic using one-way ANOVA with Dunnet post hoc test. Scale bar = 10 mm for top
row, 40 mm for the second row. Tg = transgenic; wt = wild-type.
1506 | Brain 2014: 137; 1496–1513 E. Rockenstein et al.
positive cells was determined in the frontal cortex, hippocampus, and
basal ganglia (Fig. 10A and B). In the frontal cortex, only the -
synuclein E57K Line 16 had a significant reduction in the number
of neurons compared with non-transgenic controls, whereas in the
hippocampus, there was a significant loss across -synuclein E57K
and -synuclein wild-type mice (Fig. 10B). There were no changes in
the neuronal population in the striatum (Fig. 10B). These neuronal
alterations were accompanied by a significant increase in GFAP
immunoreactivity in the neocortex and hippocampus in all mutant
-synuclein lines, as well as in Line 61 (Fig. 10C).
Behavioural deficits are exacerbated in
a-synuclein E57K compared to
a-synuclein wild-type mice
To evaluate the functional effects of the accumulation of the oligo-
mer-prone -synuclein E57K, analysis was performed using a con-
text-dependent open field test in young and older -synuclein E57K
mice and compared with non-transgenic and -synuclein wild-type
mice. As most of the neuropathological analysis was performed in the
frontal cortex and hippocampus, behavioural assessment of memory
Figure 8 Analysis of alterations in synaptic protein markers in the -synuclein E57K and -synuclein wild-type transgenic mice. (A) Brain
tissues from the fronto-temporal cortex were homogenized and separated into particulate and cytosolic fractions. The particulate fraction
was used for the immunoblot analysis. Representative immunoblot analysis of antibodies against synaptophysin, synapsin 1, SNAP25 and
RIM-3 comparing non-transgenic mice to the different -synuclein transgenic lines. (B) Analysis of integrated pixels of the immunoblot
shows a decrease in the synaptic protein synaptophysin in -synuclein E57K Line 9, and RIM-3. In -synuclein E57K transgenic mice from
synapsin 1, levels were also significantly decreased in Lines 9, 16 and 61, but not in Line 54. (C) Sections were triple-labelled with
antibodies against synaptophysin (SY38, red channel), synapsin 1 (green channel), and DAPI (blue channel) and imaged with the laser
scanning confocal microscope. The right column represents the zoomed merged image (inset). The yellow dots represent co-localization
between the two synaptic markers. (D) Image analysis of confocal images to estimate the percentage of synaptophysin terminals con-
taining synapsin 1 immunostaining. Compared with non-transgenic controls, the higher-expressing -synuclein E57K transgenic mice from
Lines 9 and 16 showed a significant reduction in co-localization, as did the -synuclein wild-type transgenic mice. No alterations were
observed in mice from Line 54 (lower expressing). n = 8 mice per group, age 8–10 months. *P50.05 when compared with non-
transgenic by one-way ANOVA with Dunnet post hoc analysis. Scale bars are 10 mm in the merged image and 5mm in the enlarged panels.
Tg = transgenic; wt = wild-type.
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acquisition was performed. At the younger age, there was a signifi-
cant interaction between time and genotype (P50.0001), in add-
ition to a significant effect as a result of time (P = 0.0003), as
evaluated using a two-way ANOVA with repeated measures.
Moreover, the young (3–4 months old) non-transgenic and lower-
expressing -synuclein E57K Line 54 mice showed habituation to the
novel environment, as evidenced by decreased activity on the last
day of testing (Fig. 11A). In contrast, -synuclein E57K Lines 9 and 16
mice displayed trends toward continued high activity and failure to
habituate (no learning; Fig. 11A). These trends were reiterated be-
tween genotypes when compared to the non-transgenic mice during
the fourth trial (Fig. 11B). At the older age, there was a significant
interaction between time and genotype (P = 0.0011), in addition to a
significant effect because of time (P = 0.0003) and genotype
(P = 0.0135), as evaluated using a two-way ANOVA with repeated
measures (Fig. 11C). Both the older, 8–10 month non-transgenic and
Figure 9 Ultrastructural and immunogold analyses of the synaptic terminals in the -synuclein E57K and -synuclein wild-type transgenic
mice. Vibratome sections were post-fixed with glutaraldehyde and embedded in Epon araldite, and ultra-thin sections from the neo-
cortex were prepared for transmitted electron microscopy (TEM) and immunogold analysis. (A) Representative electron micrographs from
the neuropil of non-transgenic mice displaying normal characteristics for presynaptic terminals (PST), post-synaptic densities, and dendrites
(d). In the neuropil of the higher expressing -synuclein E57K transgenic Lines 9 and 16, and in the -synuclein wild-type Line 61, the
synapses showed depletion of vesicles in the nerve terminals. Electrodense bodies were seen in Line 16 (arrow). (B) Image analysis of serial
micrographs to estimate the numbers of synaptic vesicles per terminal. Compared with non-transgenic controls, the higher-expressing -
synuclein E57K transgenic mouse Lines 9 and 16, and -synuclein wild-type Line 61, showed a significant reduction in the number of
vesicles. No alterations were observed in mice from Line 54 (lower expressing). (C) Representative electron micrographs from the neuropil
of non-transgenic mice immunostained with the LB509 antibody against pathological -synuclein. Only a few scattered gold particles
were detected in the neuropil. In the neuropil of the -synuclein E57K transgenic and -synuclein wild-type lines, the synapses showed
abundant gold particles clustering at the nerve terminals and mitochondria. (D) Image analysis of serial micrographs to estimate the
numbers of gold particles (LB509 reactive) per terminal. Compared with non-transgenic controls the higher-expressing -synuclein E57K
transgenic mouse Lines 9 and 16 showed a significant increase, as did -synuclein wild-type Line 61. To a lesser extent, mice from Line 54
(lower expressing) also displayed accumulation of gold particles in synapses. n = 4 mice per group, age 8–10 months. *P50.05 when
compared with non-transgenic using one-way ANOVA with Dunnet post hoc test. Scale bar = 1mm for A and B; 0.5 mm for D and E.
Tg = transgenic; wt = wild-type.
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lower expressing -synuclein E57K Line 54 mice showed habituation
and thus learning, whereas in the -synuclein E57K Line 9 there was a
significant difference in activity (P50.0001; two-way ANOVA fol-
lowed by Bonferroni multiple comparisons post hoc test). When com-
paring genotypes to the non-transgenic controls during the fourth
trial, -synuclein E57K Lines 9 and 16 and -synuclein wild-type
Line 61 were significantly different and failed to habituate to the en-
vironment (forgetting) (Fig. 11D).
Discussion
In the present study, we investigated the contribution of long-term
accumulation of -synuclein oligomers to early synaptic toxicity in
mice expressing low and high levels of oligomerization-prone
-synuclein E57K compared to -synuclein wild-type (Line 61) and
non-transgenic mice. We found that, with this artificial mutation,
-synuclein accumulates primarily in the synapses, leading to early
reduction in synaptophysin- and MAP2-immunoreactivity and alter-
ations associated with impaired localization of synapsin 1 to the
terminals. Loss of synaptic markers could indicate synaptic degener-
ation or reduced localization or expression of the protein as a result of
-synuclein accumulation in the synapse. We previously showed that
the -synuclein E57K mutant tended toward oligomerization rather
than fibril formation, and direct lentiviral vector injection of
-synuclein E57K resulted in greater dopaminergic neuronal loss
compared with other mutants and to wild-type -synuclein
(Winner et al., 2011). The tyrosine hydroxylase deficits within the
E57K viral vector model were similar to those observed with naturally
occurring mutations such as E46K. The present study is different from
this earlier study in that we investigated the effects of more wide-
spread and chronic expression of oligomer-prone -synuclein on
early synaptic pathology rather than the local acute effects on a re-
stricted circuitry, as in the experiments involving the lentiviral
injections.
Figure 10 Analysis of neurons and astroglial cells in the -synuclein E57K and -synuclein wild-type transgenic mice. Sections were
immunolabelled with antibodies against NeuN and GFAP and imaged with a digital bright field microscope. (A) Representative photo-
micrographs of the neocortex and from non-transgenic -synuclein E57K, and -synuclein wild-type Line 61 transgenic mice displaying
neuronal populations (NeuN). (B) Stereological assessment of the number of neurons in the frontal cortex, pyramidal cell layer of the CA3
of the hippocampus, and striatum was performed. In the frontal cortex, only -synuclein E57K Line 16 showed a significant decrease in the
number of NeuN-immunoreactive cells compared to non-transgenic mice. In the hippocampus, all transgenic mouse lines showed a
significant reduction in NeuN-positive cells, whereas the striatum was unaffected. (C) Astrogliosis (GFAP, inset represents higher mag-
nification) was apparent by visual inspection in -synuclein E57K Lines 9 and 16, as well as in -synuclein wild-type Line 61, and to a lesser
extent in -synuclein E57K Line 54. Scale bars: A and C = 100 mm. *P5 0.05 when compared with non-transgenic using one-way
ANOVA with Dunnet post hoc test. Tg = transgenic; wt = wild-type.
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A recent study used AAV2 to investigate the effects of aggre-
gation of -synuclein (Taschenberger et al., 2012) on the progres-
sion of neurodegeneration by expressing proline substitution
variants with different fibrillation propensities in the rat substantia
nigra. The conformational changes induced by proline substitu-
tions slowed fibril formation, most likely by impairing -helix for-
mation. Although these proline substitutions (A30P/A56P/A76P)
had a pathologic effect when combined in rat cortical neurons and
Caenorhabditis elegans, formation of proteinase K-resistant -
synuclein aggregates was associated with loss of nigral dopamin-
ergic neurons and striatal fibres. Expression of two prefibrillar,
structure-based design mutants of -synuclein (i.e. A56P and
A30P/A56P/A76P) resulted in some neuronal loss in nigral
dopaminergic neurons. However, only the -synuclein variants
capable of forming fibrils (wild-type/A30P) induced a sustained
progressive loss of adult nigral dopaminergic neurons. These
AAV-based systems had slower onset of tyrosine hydroxylase
loss, depending on the promoter, between 4 and 24 weeks (St
Martin et al., 2007; Taschenberger et al., 2012). The differences
seen between models might differ in the extent and duration of
prefibrillar toxicity. Burre et al. (2012) also introduced different
proline substitutions by injecting a lentivirus construct into
mouse substantia nigra. Depending on the localization of the mu-
tation within -synuclein, the introduction of these mutational
changes by proline substitution were able to induce dopaminergic
loss within the NAC region (residues 61–95) and in the familial
Figure 11 Memory alterations in the -synuclein E57K and -synuclein wild-type transgenic mice. Mice were evaluated for context-
dependent learning in an open field area first at 3–4 months of age and then at 8–10 months in a Kinder SmartFrame Cage Rack Station
activity monitor system. (A) At 3–4 months of age, non-transgenic controls and -synuclein E57K transgenic Line 54 (lower-expressing)
mice had reduced levels of activity over time as they became more familiar with the environment in the cage. The -synuclein E57K
transgenic mice from Lines 9 and 16 and the -synuclein wild-type Line 61 transgenic mice showed a similar level of activity over time. (B)
Evaluation of the fourth day of assessment compared to non-transgenic mice suggested trends toward dishabituation in -synuclein E57K
Line 9 and -synuclein wild-type Line 61 (one-way ANOVA with Dunnett’s multiple comparisons post hoc test). (C) Both the older 8–10
month non-transgenic and lower-expressing -synuclein E57K Line 54 mice showed habituation and thus learning, whereas in the -
synuclein E57K Line 9 there was a significant difference in activity (P5 0.0001; two-way ANOVA followed by Bonferroni multiple
comparisons post hoc test). (D) When comparing genotypes to the non-transgenic controls during the fourth trial, -synuclein E57K Lines
9 and 16 and -synuclein wild-type Line 61 were significantly different and failed to habituate to the environment (forgetting). n = 12
non-tg, n = 7 -synuclein E57K Line 9, n = 8 -synuclein E57K Line 16, n = 14 -synuclein E57K Line 54, n = 14 -synuclein wild-type Line
61 mice per age group. *P5 0.05; ***P50.001 when compared with non-transgenic by one-way ANOVA with Dunnet post hoc
analysis. Tg = transgenic; wt = wild-type; m/o = month old.
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A30P mutation, but not in mutations between residues 31 and 59.
In addition, these mutations do not have an impact on the physio-
logical role of -synuclein in synaptic vesicles. In contrast, in this
system the familial A53T, E46K mutations also had a major in-
crease in pathology (Burre et al., 2012). We therefore concluded
that proline substitutions might induce more selective toxicity. The
difference between our results and those of the study by
Taschenberger et al., (2012) can be explained by differences in
-synuclein structure and synaptic function induced by E–K muta-
tions (negative charge to positive charge) that either led to differ-
ent forms of prefibrillar structures or had differential impact on
nucleation of aggregation of -synuclein wild-type.
As behavioural and neurodegenerative pathology was present
primarily in the higher-expressing mice as compared with the
lower-expressing line, this implies a dose-dependent effect.
Although the mutation we used is artificial, the -synuclein oligo-
mers are biochemically and ultrastructurally similar to those
described with -synuclein wild-type and with familial mutants
such as A53T (Lashuel et al., 2002). Although the identity of
toxic -synuclein conformers and species in vivo are intensely
investigated, it is clear from this and other studies that oligomer-
ization plays a central role in neurodegeneration and the damage
begins at the synaptic site and spreads back to the axons and
neuronal cell bodies. For example, in the brains of patients with
Parkinson’s disease and dementia with Lewy bodies, proteinase K-
resistant -synuclein accumulates primarily at the nerve terminals,
where it might affect synaptic function and axonal transport
(Kahle et al., 2001; Scott et al., 2010). Similar proteinase K-resist-
ant -synuclein aggregates were detected in synapses and axons
of -synuclein E57K mice. These proteinase K-resistant -synuclein
deposits correlate with synaptic and dendritic damage in dementia
with Lewy bodies/Parkinson’s disease (Schulz-Schaeffer, 2010).
The precise mechanisms through which -synuclein oligomers
might damage the synapse are not completely understood; how-
ever, interference with synaptic vesicle proteins (Burre et al., 2010;
Fortin et al., 2010; Choi et al., 2013), axonal transport (Scott
et al., 2010), calcium homeostasis (Danzer et al., 2007;
Reznichenko et al., 2012) and mitochondrial function (Nakamura
et al., 2008) are involved. Consistent with the possibility that -
synuclein oligomers might impair synaptic function by interfering
with the vesicles, the present study showed that the oligomer-
prone -synuclein E57K accumulated at the presynaptic site,
where they might disrupt the presynaptic localization of synapsin
1, which is essential for vesicle clustering in the active zone
(Shupliakov et al., 2011). In addition, the synapses had fewer
synaptic vesicles, which is in agreement with a previous study
which showed that in the brains of patients with dementia with
Lewy bodies/Parkinson’s disease and in primary neuronal cultures
from -syn:GFPe transgenic mice, synapsin 1 is mislocalized, which
impairs overall synaptic function and plasticity (Scott et al., 2010)
and results in deficient long term potentiation (Diogenes et al.,
2012). The mechanisms through which synaptic oligomers disrupt
synaptic vesicle function are under intense investigation. A recent
study showed that dopamine-induced, large -synuclein oligomers
effectively inhibit neuronal Soluble NSF Attachment Protein
Receptor (SNARE)-mediated vesicle lipid mixing by preferentially
binding to the SNARE protein, synaptobrevin 2 (Choi et al., 2013).
In addition, large -synuclein oligomers reduced vesicular exocyt-
osis in PC12 cells (Choi et al., 2013). Another interesting synaptic
protein affected by the mutant -synuclein was RIMS3. RIMs 1-3
are effector proteins for Rab3s, synaptic GTP-binding proteins.
RIMs are localized close to the active zone at the synapse,
where they interact in a GTP-dependent manner with Rab3s
located on synaptic vesicles (Wang et al., 2000). We currently
do not have direct evidence for the interaction of the -synuclein
oligomers with RIMS3 or Rab3s proteins; however, this is a po-
tential mechanism through which -synuclein could disrupt synap-
tic vesicle localization. Further investigation will be needed in the
future.
-Synuclein can associate with cell membranes, including synap-
tic vesicles, retrograde axonal transport vesicles, and detergent-re-
sistant membrane-microdomains (Maroteaux et al., 1988; Jensen
et al., 1998; Cole et al., 2002; Outeiro and Lindquist, 2003; Fortin
et al., 2004). We therefore used different detergents (TritonTM X-
100, SDS) and a chaotropic reagent (urea) to study the solubility and
equilibrium of -synuclein and its multimers at distinct neuronal
structures. Consistent with our previous finding that -synuclein
oligomers are prone to form membrane-assembling multimeric ag-
gregates (Tsigelny et al., 2007), which is further increased by the
‘conformation-trapped’ -synuclein E57K mutation (Winner et al.,
2011), we detected a specific SDS/urea-stable -synuclein multimer
in E57K transgenic mice, and in homogenates from dementia with
Lewy bodies cases. Unlike -synuclein E57K, -synuclein wild-type
oligomers dissolve mainly as an unspecific higher-molecular smear
and its monomer (Kahle et al., 2002; Tofaris et al., 2006). The sta-
bility of the multimer suggests that the protein may be rigid, similar
to other multimeric membrane proteins (le Coutre et al., 1998;
Hibino and Kurachi, 2007). It is possible that tight association with
detergent-resistant membrane fractions such as lipid-rafts (Fortin
et al., 2004) or conformational changes induced by integration
into the membrane stabilize the -synuclein E57K multimer, whereas
-synuclein wild-type aggregates are less membrane-associated and
therefore dissociate into multiple higher-oligomeric and monomeric
species in the presence of SDS/urea mixture. This observation is
supported by new evidence that amyloid and oligomeric structures
display a higher tendency to disrupt lipid formations of plasma mem-
branes (Reynolds et al., 2011; Barrett et al., 2012). Therefore, the
aggregates formed by the -synuclein E57K (pentameric) and
-synuclein wild-type (monomeric) lines suggest structural similari-
ties with urea-insoluble multimeric and monomeric -synuclein
detected in dementia with Lewy body cases.
Although higher-expressing -synuclein E57K mice displayed
similar levels of synaptic degeneration and neuronal loss in the
hippocampus when compared to the -synuclein wild-type mice,
they differed in that the oligomer-prone mice displayed more
severe synaptic pathology, behavioural differences and neuronal
loss in the frontal cortex. This finding is consistent with the con-
cept that oligomers drive the neurodegenerative process in de-
mentia with Lewy bodies/Parkinson’s disease in a significant
manner. Failure to form fibrils, as was the case in the -synuclein
E57K lines, was associated with exacerbating pathology. In the
case of the -synuclein wild-type Line 61 mice, both oligomers
and fibrillar (FILA-1 immuoreactivity) -synuclein were present,
suggesting that the conversion of -synuclein toward fibrillar
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structures may attenuate the extent of the neurodegeneration and
behavioural deficits.
In summary, this study supports the hypothesis that synaptic
pathology, which is common to dementia with Lewy bodies and
Parkinson’s disease with dementia and is an early pathological
consequence of -synuclein accumulation, may be mediated by
oligomeric -synuclein interfering with the synaptic vesicles, lead-
ing to neuronal loss. Moreover, this oligomer-prone model might
be useful for evaluating therapies directed at oligomer reduction.
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